About Errant Gene

Errant Gene Therapeutics, LLC™ (EGT) is a privately held biopharmaceutical company established in 2003. The company’s mission is the development of treatments for life-threatening diseases with a special focus on rare diseases, commonly referred to as “orphan diseases.” EGT is developing its portfolio of pharmaceutical products to correct the erroneous gene expression associated with many of these diseases. EGT therapies are currently being developed for hemoglobinopathies and selected cancers.

EGT’s product portfolio is the result of license agreements to technology for exclusive world-wide rights and the acquisition of a library of novel pharmaceutical molecules. Two products are poised to enter into clinical development.